By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

The New England Journal of Medicine 

10 Shattuck Street

Boston  Massachusetts  02115-6094  U.S.A.
Phone: 617-734-9800 Fax: 617-739-9864


SEARCH JOBS


Industry
Services

Segment
Publisher





Company News
Gilead (GILD) Release: Results From The AMBITION Study Of First-Line Treatment With Letairis And Tadalafil In Pulmonary Arterial Hypertension Published In The New England Journal of Medicine 8/27/2015 10:43:15 AM
Genmab A/S (GEN.CO) Release: Data Published In The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses In Heavily Pre-Treated Relapsed Or Refractory Multiple Myeloma Patients 8/27/2015 7:16:19 AM
Janssen Research & Development Release: Data Published In The New England Journal of Medicine Show Single-Agent Daratumumab Demonstrated A 36 Percent Overall Response Rate And Tolerable Safety Profile In Heavily Pre-Treated Multiple Myeloma Patients 8/27/2015 6:15:01 AM
Isis Pharma (ISIS) Release: Positive Clinical Data From Volanesorsen Published In The New England Journal of Medicine 7/30/2015 11:36:38 AM
Sarepta (SRPT) Announces The New England Journal of Medicine Publication Of Phase I Clinical Data Of Marburg Drug Candidate, AVI-7288, Supporting Safety Of The Pmoplus Platform 7/23/2015 10:56:28 AM
Efficacy Results Of Otsuka Pharma’s Delamanid (Deltyba) For Extensively Drug-Resistant Tuberculosis (XDR-TB) Published In The New England Journal of Medicine 7/16/2015 11:12:48 AM
C. R. Bard, Inc. (BCR) Release: The New England Journal of Medicine Publishes LEVANT 2 Results For The Lutonix Drug Coated Balloon, Showing Superior Efficacy Compared To Standard PTA 6/25/2015 12:32:50 PM
Bristol-Myers Squibb (BMY) Release: Adding Investigational Agent Elotuzumab To Standard Treatment For Multiple Myeloma Significantly Reduced The Risk Of Disease Progression, According To New Phase III Data From ELOQUENT-2 Trial Published In The New England Journal of Medicine 6/2/2015 11:14:45 AM
ASCO15: First Study Evaluating DNA Mismatch Repair As Genetic Guide For Immunotherapy Treatment With Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) Presented At 2015 ASCO Annual Meeting And Published In The New England Journal of Medicine 6/1/2015 2:30:44 PM
Vertex (VRTX) Release: The New England Journal of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (Lumacaftor/Ivacaftor) In People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation 5/18/2015 11:24:35 AM
12345678910...
//-->